Abonnement à la biblothèque: Guest
Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections
Critical Reviews™ in Immunology
Facteur d'impact: 1.352 Facteur d'impact sur 5 ans: 3.347 SJR: 0.657 SNIP: 0.55 CiteScore™: 2.19

ISSN Imprimer: 1040-8401
ISSN En ligne: 2162-6472

Volumes:
Volume 39, 2019 Volume 38, 2018 Volume 37, 2017 Volume 36, 2016 Volume 35, 2015 Volume 34, 2014 Volume 33, 2013 Volume 32, 2012 Volume 31, 2011 Volume 30, 2010 Volume 29, 2009 Volume 28, 2008 Volume 27, 2007 Volume 26, 2006 Volume 25, 2005 Volume 24, 2004 Volume 23, 2003 Volume 22, 2002 Volume 21, 2001 Volume 20, 2000 Volume 19, 1999 Volume 18, 1998 Volume 17, 1997 Volume 16, 1996 Volume 15, 1995 Volume 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.2013006782
pages 415-434

Infectious Tolerance as Candidate Therapy for Type 1 Diabetes: Transfer of Immunoregulatory Properties from Human Regulatory T Cells to Other T Cells and Proinflammatory Dendritic Cells

Fleur S. Kleijwegt
Department of Immunohematology & Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands
Bart O. Roep
Department of Immunohematology & Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands

RÉSUMÉ

Type 1 diabetes is a T-cell−mediated autoimmune disease in which the insulin-producing cells in the islets of Langerhans are selectively destroyed. Although symptomatic insulin therapy is able to control glucose levels in the blood, many patients do not obtain the desired glycemic control, which increases the risk of diabetic complications. While many immunotherapeutic efforts to intervene in the disease process focus on systemic immune-suppressive therapies, antigen-specific immune modulation represents an attractive alternative. Dendritic cells modulated with 1.25(OH)2 vitamin D3, and dexamethasone (tolerogenic DCs) loaded with islet antigens induce Ag-specific regulatory CD4 T cells (iaTregs), offering a tissue-specific intervention therapy. iaTregs exert their function via linked suppression to diminish effector cells by modulating pro-inflammatory DCs to upregulate inhibitory receptors. In turn, these re-educated mature DCs induce IL-10−producing cells from the naive T-cell pool. Thus, tolerogenic DCs transfer regulatory properties to pro-inflammatory DCs via iaTregs (i.e., infectious tolerance). In this review, we describe the current knowledge regarding regulatory mechanisms of these tolerogenic DCs and the Tregs that they induce, and we propose that cell therapy with human tolerogenic DCs provides new opportunities for immune intervention in patients with autoimmune diseases.


Articles with similar content:

Antigen-Specific Tolerance in Immunotherapy of Th2-Associated Allergic Diseases
Critical Reviews™ in Immunology, Vol.33, 2013, issue 5
Paul J. Bryce, Charles B. Smarr, Stephen D. Miller
Regulation of Antigen-Specific Regulatory T-Cell Induction via Nasal and Oral Mucosa
Critical Reviews™ in Immunology, Vol.24, 2004, issue 3
Janneke N. Samsom
Understanding How Lipopolysaccharide Impacts CD4 T-Cell Immunity
Critical Reviews™ in Immunology, Vol.28, 2008, issue 4
Anthony T. Vella, Jeremy P. McAleer
Effect of Lymphodepletion on Donor T Cells and the Role of Recipient Cells Persisting after Cytotoxic Treatments in Cancer Immunotherapies
Critical Reviews™ in Immunology, Vol.37, 2017, issue 1
Toshiaki Kikuchi, Toshiyuki Koya, Masashi Arita, Miho Takahashi, Yu Saida, Satoshi Watanabe
NK Cells and Their Ability to Modulate T Cells during Virus Infections
Critical Reviews™ in Immunology, Vol.34, 2014, issue 5
Kevin D. Cook, Stephen N. Waggoner, Jason K. Whitmire